Scholarlink

<p>A live attenuated chikungunya vaccine, IXCHIQ, was approved in the United States in 2023 for use in adults. We assessed the cost-effectiveness of two different vaccination strategies, routine and outbreak vaccination, for persons aged ≥18 years living in U.S. territories with previous transmission. We included the entire population of impacted U.S. territories and assumed one chikungunya outbreak occurring during a 30-year time horizon. We estimated that routine vaccination would avert 90% of the disease burden and cost $498 million (16% savings compared with no vaccination) while outbreak vaccination would avert 67% of the disease burden and cost $552 million (6% savings). Both strategies were more costly than no vaccination from the healthcare payer perspective. Routine vaccination was cost-saving for all outcomes assessed from a societal perspective. Outbreak vaccination was cost-saving for averted symptomatic cases but cost from $5 [95% CI: cost savings, $191] per chronic joint pain case averted to $373,054 [95% CI: $172,643, $573,464] per death averted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness of chikungunya vaccination with the live attenuated vaccine in U.S. territories

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Kelly Kilburn,
  • Martin I. Meltzer,
  • Seonghye Jeon,
  • Bishwa B. Adhikari,
  • Nicole Lindsey,
  • Susan L. Hills,
  • J. Erin Staples

摘要

A live attenuated chikungunya vaccine, IXCHIQ, was approved in the United States in 2023 for use in adults. We assessed the cost-effectiveness of two different vaccination strategies, routine and outbreak vaccination, for persons aged ≥18 years living in U.S. territories with previous transmission. We included the entire population of impacted U.S. territories and assumed one chikungunya outbreak occurring during a 30-year time horizon. We estimated that routine vaccination would avert 90% of the disease burden and cost $498 million (16% savings compared with no vaccination) while outbreak vaccination would avert 67% of the disease burden and cost $552 million (6% savings). Both strategies were more costly than no vaccination from the healthcare payer perspective. Routine vaccination was cost-saving for all outcomes assessed from a societal perspective. Outbreak vaccination was cost-saving for averted symptomatic cases but cost from $5 [95% CI: cost savings, $191] per chronic joint pain case averted to $373,054 [95% CI: $172,643, $573,464] per death averted.